Echosens Presents Research at 2021 AASLD Liver Meeting: Early Detection and Monitoring with FibroScan Mitigates Risk of Patients Developing Fibrosis/Cirrhosis
11.11.2021 16:53:00 EET | Business Wire | Press release
Echosens, a high-technology company offering the FibroScan® family of products, is pleased to announce its strong presence at the upcoming American Association for the Study of Liver Diseases (AASLD) Liver Meeting, a digital conference, Nov. 12-15, 2021, with FibroScan-based solutions - referenced in 19 oral presentations and 180 poster presentations. They include new results demonstrating the clinical usefulness of liver and spleen stiffness measurement by VCTE as well as CAP but also further confirm the performances of Fast™, Agile 3+, Agile 4 and FibroMeter VCTE scores in many different settings.
“Non-invasive FibroScan is an innovative technology that advances efforts to halt the progression of fatty liver disease (FLD) and empowers healthcare providers with an accurate, point-of-care tool to measure liver fat and stiffness,” says Dominique Legros, Group CEO, Echosens. “Our technology solutions serve as the cornerstone of non-invasive tests for the future of liver disease management—across the liver care continuum and all population groups. With better assessment tools in primary care, unnecessary specialist referrals and more invasive and expensive diagnostic testing can be reduced.”
FLD includes nonalcoholic fatty liver disease (NAFLD), the accumulation of liver fat in people who drink little or no alcohol, and its more severe form nonalcoholic steatohepatitis (NASH).
NAFLD is often present as a comorbidity in patients with Type 2 diabetes. The mutual interrelationship between these conditions shows that Type 2 diabetes can exacerbate NAFLD by promoting progression to NASH, often leading to fibrosis and cirrhosis, while NAFLD causes the natural course of diabetic complications to worsen in Type 2 diabetes patients.
NAFLD affects about 25% of people in the world. As the rates of obesity, Type 2 diabetes and high cholesterol rise, so does the rate of NAFLD. FibroScan is acknowledged worldwide and validated by over 3,000 peer reviewed publications and 140 international guidelines across 100+ countries.
Jon Gingrich, CEO, Echosens North America, says, “This important conference allows us to showcase FibroScan as a valuable innovation that can improve care and reduce costs for managing chronic liver conditions. The expanding body of data supports FibroScan as an early assessment and monitoring tool that can mitigate the risk that patients will develop more serious conditions like fibrosis, cirrhosis and liver cancer.”
About Echosens
Pioneer in its field, Echosens significantly changed the practice of liver assessment with FibroScan®, the non-invasive solution for comprehensive management of liver health. FibroScan® is recognized worldwide and validated by over 3,000 peer reviewed publications and 140 international guidelines. Echosens has made FibroScan® available in over 100+ countries enabling millions of liver examinations worldwide. https://www.echosens.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211111005332/en/
Contact information
Media:
Brittany Tedesco
CPR Communications
btedesco@cpronline.com
201.641.1911 x 14
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 03:30:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re excited at the potential to fundamentally change how NT1 is managed across Japan and China,” said Giles Platford, president, International, Takeda. “We’ve heard from patients how ORZEYFUL has improved their daily functioning and quality of life, enormously meaningful outcomes for a condition known to impact many aspects of a person’s life, including work, education and social interactions.”1,2,3,4,5 NT1 is a chronic, rare neurological disease driven by orexin deficiency. People experience a range of symptoms including excessive daytime sleepiness, cataplexy (sudden loss of muscle tone), disr
Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 03:10:00 EEST | Press release
Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to expand treatment options for patients with IBD.2,3 On October 18, Celltrion will host a symposium titled "Navigating the Treatment Journey with Subcutaneous Infliximab Across Clinical Scenarios," Chaired by Professor Peter M. Irving of King's College London, UK, a leading IBD expert. Celltrion will also host two MTE sessions at its booth. In the firs
ProcureTEX Returns for Its Second Year, Bringing AI and Best-of-Breed Procurement Technology to Amsterdam14.10.2026 19:26:00 EEST | Press release
ProcureTEX, the community-driven event for best-of-breed procurement technology, returns for its second year on November 3, 2026, at Circa in Amsterdam. Following its London debut in 2025, the event sharpens its focus on how AI is reshaping procurement. It will bring together over 250 procurement leaders and digital transformation teams from large enterprises, with vetted best-of-breed technology providers, to see AI agents and interoperable tools working together on real enterprise challenges. Co-founded by Beroe, Keelvar and Zip, the event is built on the belief that the future of procurement isn’t a monolithic all-in-one suite, but an ecosystem of best-of-breed tools working together. It is designed for procurement and enterprise leaders seeking scalable, modern solutions, whether they’re driving transformation, frustrated with outdated tools, or looking to connect with peers solving similar problems and putting AI to work. Renowned technology analyst and former Andreessen Horowitz
eM Client 11 Launches: A European Outlook Alternative Bringing AI Freedom, Digital Sovereignty, and Next-Generation Productivity14.10.2026 19:16:00 EEST | Press release
eM Client, the European developer of the popular email and productivity application used by millions worldwide, today announced the release of eM Client 11, its most significant update yet. The new version introduces advanced AI capabilities, and major productivity improvements, strengthening its position as an independent alternative to Microsoft Outlook. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014945464/en/ eM Client 11 main window AI Without Vendor Lock-In eM Client 11 introduces a powerful AI Assistant that enables users to search, summarize, organize, and manage emails using natural language. Additional features include personalized AI writing, context-aware quick replies, automatic task and event detection, and AI-powered email rules. Unlike traditional AI integrations, eM Client 11 supports Bring Your Own Key (BYOK), allowing organizations to connect compatible AI providers and models of their choice. The re
iQmetrix and Stratus HR Partner to Give Wireless Retailers a Complete, Outsourced HR Department14.10.2026 18:15:00 EEST | Press release
Stratus HR, a full-service human resources outsourcing provider, today announced a partnership with iQmetrix, the Intelligent Commerce Operating System for telecom. As a Professional Employer Organization (PEO), Stratus HR becomes the complete, outsourced HR partner for wireless retailers on iQmetrix – payroll, benefits, compliance, and on-call HR experts – so retail teams stay focused on selling and serving customers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014178512/en/ Fully integrated with iQmetrix, Stratus HR’s custom-built technology connects the employee lifecycle to the store: new hires, terminations, rehires, position moves, and security-role updates flow straight into the point of sale (POS), while hours flow from the retailer’s iQmetrix system into payroll – eliminating double entry and pay errors, so every paycheck is accurate and every new hire hits the floor faster. Frontline teams get enterprise-leve
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom